Literature DB >> 3541978

Corneal graft survival: a retrospective Australian study.

V L Bishop, L P Robinson, A W Wechsler, F A Billson.   

Abstract

Four hundred and forty-eight consecutive corneal grafts are analysed and their survival calculated using the actuarial life-table method. Overall survival at two years is 81 +/- 4% and at five years is 65 +/- 5%. Within diagnostic subgroups keratoconus has the best prognosis. Previous graft failure and recipient corneal vascularization are shown to have a negative effect on graft survival. Sex of patient, urgency of operation and use of combined procedures do not affect survival and second regrafts fare no worse than first regrafts. The use of the actuarial life-table method of analysing graft survival is discussed and its importance emphasized.

Entities:  

Mesh:

Year:  1986        PMID: 3541978     DOI: 10.1111/j.1442-9071.1986.tb00024.x

Source DB:  PubMed          Journal:  Aust N Z J Ophthalmol        ISSN: 0814-9763


  4 in total

1.  Survival analysis and visual outcome in a large series of corneal transplants in India.

Authors:  L Dandona; T J Naduvilath; M Janarthanan; K Ragu; G N Rao
Journal:  Br J Ophthalmol       Date:  1997-09       Impact factor: 4.638

2.  Long-term results of penetrating keratoplasty. A 10-year-plus retrospective study.

Authors:  Marc Muraine; Christian Sanchez; Laure Watt; Alain Retout; Gérard Brasseur
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-06-18       Impact factor: 3.117

3.  Indications and outcomes of pediatric keratoplasty in a tertiary eye care center: A retrospective review.

Authors:  Rosario Gulias-Cañizo; Roberto Gonzalez-Salinas; Luis Fernando Hernandez-Zimbron; Everardo Hernandez-Quintela; Valeria Sanchez-Huerta
Journal:  Medicine (Baltimore)       Date:  2017-11       Impact factor: 1.817

4.  Penetrating keratoplasty in south east London 1981-1986: epidemiological aspects and demands on medical resources.

Authors:  C Claoué; M Falcon; J Shilling
Journal:  J R Soc Med       Date:  1990-04       Impact factor: 18.000

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.